Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions

doi:10.4254/wjh.v18.i5.118303

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(26)

(28)

(0)

(45)

(1287)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. May 27, 2026; 18(5): 118303
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.118303

Full Size Figure Download Figure

Figure 2 Challenges and obstacles to the use of anti-obesity medications in metabolic dysfunction-associated fatty liver disease and metabolic associated steatotic liver disease. MAFLD: Metabolic dysfunction-associated fatty liver disease; MASLD: Metabolic associated steatotic liver disease; HCC: Hepatocellular carcinoma.

Citation: Fouad Y, Abdelghany WA, El Sheemy R. Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions. World J Hepatol 2026; 18(5): 118303
URL: https://www.wjgnet.com/1948-5182/full/v18/i5/118303.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i5.118303

Fouad Y, Abdelghany WA, El Sheemy R. Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions. World J Hepatol 2026; 18(5): 118303 [DOI: 10.4254/wjh.v18.i5.118303]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.